INSERM (French Institut of Health and Medical Research), UMR1098 (Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire Et Génique), EFS BFC (Etablissement Français du Sang Bourgogne Franche-Comté), University of Bourgogne Franche-Comté, RIGHT Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire Et Génique, 25000, Besançon, France.
Biostatistics Unit, Department of Clinical Research and Innovation & Department of Human and Social Sciences, Centre Léon Bérard, Lyon, France.
Qual Life Res. 2022 Oct;31(10):3077-3085. doi: 10.1007/s11136-022-03157-4. Epub 2022 May 19.
The potential effects of breast cancer (BC) on health-related quality of life (HRQoL) should be considered in clinical and policy decision-making, as the economic burden of BC management is currently assessed. In the last decades, time-to-HRQoL score deterioration (TTD) has been proposed as an approach to the analysis of longitudinal HRQoL in oncology. The main objectives of the current study were to investigate the evolution of the utility values in BC patients after diagnosis and during follow-ups and to evaluate the TTD in utility values among women in all stages of BC.
Health-state utility values (HSUV) were assessed using the EuroQol 5-Dimension 3-Level at diagnosis, at the end of the first hospitalization and 3 and 6 months after the first hospitalization. For a given baseline score, HSUV was considered to have deteriorated if this score decreased by ≥ 0.08 points of the EQ-5D utility index score and ≥ 7 points of the EQ visual analogue scale. TTD curves were calculated using the Kaplan-Meier estimation method.
Overall 381 patients were enrolled between February 2006 and February 2008. The highest proportions of respondents at the baseline and all follow-ups reporting some and extreme problems were in pain discomfort and anxiety/depression dimensions; more than 80% of patients experienced a deterioration in EQ-5D utility index score and EQ VAS score with a median TTD of 3.15 months and 6.24 Months, respectively.
BC patients undergoing therapy need psychological support to cope with their discomfort, pain, depression, anxiety, and fear during the process of diagnosis and treatment to improve their QoL.
在进行临床和政策决策时，应考虑乳腺癌（BC）对健康相关生活质量（HRQoL）的潜在影响，因为目前正在评估 BC 管理的经济负担。在过去的几十年中，健康相关生活质量评分恶化时间（TTD）已被提出作为肿瘤学中分析纵向 HRQoL 的一种方法。本研究的主要目的是调查诊断后和随访期间 BC 患者的效用值演变，并评估 BC 各阶段女性的效用值 TTD。
使用 EuroQol 5 维度 3 水平量表在诊断时、第一次住院结束时以及第一次住院后 3 个月和 6 个月评估健康状态效用值（HSUV）。对于给定的基线评分，如果该评分在 EQ-5D 效用指数评分中降低了≥0.08 分，或在 EQ 视觉模拟量表中降低了≥7 分，则认为 HSUV 恶化。使用 Kaplan-Meier 估计方法计算 TTD 曲线。
2006 年 2 月至 2008 年 2 月期间共纳入 381 名患者。在基线和所有随访中，报告有某些和极端问题的比例最高的是疼痛不适和焦虑/抑郁维度；超过 80%的患者经历了 EQ-5D 效用指数评分和 EQ VAS 评分的恶化，中位 TTD 分别为 3.15 个月和 6.24 个月。
接受治疗的 BC 患者在诊断和治疗过程中需要心理支持来应对不适、疼痛、抑郁、焦虑和恐惧，以提高他们的生活质量。
